MEI Pharma reports Q3 EPS (39c) vs ($1.37) last year

As previously announced in July 2024, the Company is continuing its review and evaluation of potential strategic alternatives. As part of this assessment, the Company is considering options such as out-licensing opportunities for existing programs and merger and acquisition opportunities, with the goal of maximizing the value of its assets for its stockholders. Oppenheimer & Co., Inc. is serving as the Company’s exclusive financial advisor in this process. Through the third quarter of fiscal year 2025, the Company’s cash preservation efforts continue and include a reduction-in-force progressing in stages as the Company’s operational and strategic direction evolves. As of March 31, 2025, the Company had $20.5 million in cash and cash equivalents with no outstanding debt.